Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
Author:
Funder
North Central Cancer Treatment Group
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/25/10/2020/23872146/mdu273.pdf
Reference27 articles.
1. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine;Romaguera;J Clin Oncol,2005
2. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma;Romaguera;Br J Haematol,2010
3. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
4. Autologous stem cell transplantation (ASCT) in first remission for patients with mantle cell lymphoma is associated with a prolonged survival;Siddiqui;Ann Oncol,2005
5. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma;Murali;Bone Marrow Transplant,2008
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects;International Journal of Molecular Sciences;2023-09-14
2. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer;Molecular Cancer;2023-08-18
3. Clinical Experiences with Drugs Targeting m TOR;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15
4. Mantle cell lymphoma management trends and novel agents: where are we going?;Therapeutic Advances in Hematology;2022-01
5. Synthesis of 2-Chloro-2′-Deoxyadenosine (Cladribine) and New Purine Modified Analogues;Journal of New Developments in Chemistry;2021-11-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3